Søren Weis Dahl
Vorstandsvorsitzender bei Deck Therapeutics, Inc.
Aktive Positionen von Søren Weis Dahl
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Deck Therapeutics, Inc.
 Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deck Therapeutics, Inc. is an American acute omega-3 fatty acid therapeutics development company. Søren Weis Dahl has been the CEO of the company since 2020. | Direktor/Vorstandsmitglied | 01.01.2014 | - |
| Vorstandsvorsitzender | 01.01.2014 | - |
Karriereverlauf von Søren Weis Dahl
Ehemalige bekannte Positionen von Søren Weis Dahl
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| PILA PHARMA AB | Direktor/Vorstandsmitglied | 30.05.2023 | 01.04.2024 |
Prophylix AS
 Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Vorstandsvorsitzender | 01.04.2015 | 01.01.2019 |
Ausbildung von Søren Weis Dahl
| Copenhagen Business School | Masters Business Admin |
| Technical University of Denmark | Graduate Degree |
Statistik
International
| Dänemark | 3 |
| Norwegen | 2 |
| Schweden | 2 |
Operativ
| Chief Executive Officer | 2 |
| Director/Board Member | 2 |
| Graduate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PILA PHARMA AB | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Prophylix AS
Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Health Technology |
Deck Therapeutics, Inc.
Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deck Therapeutics, Inc. is an American acute omega-3 fatty acid therapeutics development company. Søren Weis Dahl has been the CEO of the company since 2020. | Health Technology |
- Börse
- Insiders
- Søren Weis Dahl
- Erfahrung
